Cannabidiol
| Evidence Level: L5 | Predicted Indications: 53 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Cannabidiol |
| DrugBank ID | DB09061 |
| Brand Names (EU) | Epidyolex |
| Evidence Level | L5 |
| Predicted Indications | 53 |
| Top Prediction Score | 96.17% |
Approved Indication (EMA)
Epidyolex is indicated for use as adjunctive therapy of seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome (DS), in conjunction with clobazam, for patients 2 years of age and older.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | restless legs syndrome | 96.17% | DL |
| 2 | bilateral parasagittal parieto-occipital polymicrogyria | 95.99% | DL |
| 3 | axial spondylometaphyseal dysplasia | 94.22% | DL |
| 4 | amyotrophic lateral sclerosis | 94.15% | DL |
| 5 | trichomegaly-retina pigmentary degeneration-dwarfism syndrome | 93.83% | DL |
| 6 | episodic kinesigenic dyskinesia | 93.73% | DL |
| 7 | Mills syndrome | 93.41% | DL |
| 8 | amyotrophic lateral sclerosis, susceptibility to | 93.40% | DL |
| 9 | lower motor neuron syndrome with late-adult onset | 93.21% | DL |
| 10 | lethal arthrogryposis-anterior horn cell disease syndrome | 93.18% | DL |
| 11 | monomelic amyotrophy | 93.07% | DL |
| 12 | amyotrohpic lateral sclerosis type 22 | 92.89% | DL |
| 13 | PURA-related severe neonatal hypotonia-seizures-encephalopathy syndrome due to a point mutation | 92.39% | DL |
| 14 | neonatal period electroclinical syndrome | 92.30% | DL |
| 15 | 1q44 microdeletion syndrome | 92.22% | DL |
| 16 | myoclonic epilepsy, Hartung type | 92.01% | DL |
| 17 | developmental and epileptic encephalopathy | 91.99% | DL |
| 18 | genetic lethal multiple congenital anomalies/dysmorphic syndrome | 91.92% | DL |
| 19 | autosomal dominant mitochondrial myopathy with exercise intolerance | 91.88% | DL |
| 20 | infancy electroclinical syndrome | 91.85% | DL |
Showing top 20 of 53 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.